Maged Shenouda has bought stock on 7 days since Dec 2018

Maged Shenouda is the Chief Financial Officer (CFO) of Relmada Therapeutics, Inc. (RLMD), a clinical-stage biotechnology company focused on central nervous system diseases, a role he has held since January 2020 after transitioning from the company's Board of Directors where he served since November 2015.( Aged 60, Shenouda brings over 30 years of experience in biotechnology, pharmaceuticals, and equity research, including prior CFO and director positions at AzurRx Biopharma (2015–2019), Head of Business Development & Licensing at Retrophin, Inc. (2014), and senior equity research analyst roles at UBS, JPMorgan, Stifel Nicolaus, Citigroup, and Bear Stearns.(

Shenouda began his career in pharmaceutical sales as a hospital representative and managed care specialist at Abbott Laboratories, followed by management consulting at PwC's Pharmaceutical Consulting practice.( He holds a B.S. in Pharmacy from St. John's University, where he is a registered pharmacist in New Jersey and California, and an MBA from Rutgers Graduate School of Management.( Under his financial leadership at Relmada, the company has emphasized capital discipline amid challenges like a sharp decline in total shareholder return in 2024 and a net loss of $79.98M, prioritizing assets such as NDV-01 and sepranolone while withholding executive bonuses following a negative say-on-pay vote.(

Written by Perplexity from public sources.